Clinical Trials at Roswell Park Comprehensive Cancer Center
As of September 2026, 43 paid clinical trials are recruiting at Roswell Park Comprehensive Cancer Center, located at Roswell Pk Comprehensive Cancer Ctr, 665 Elm St, Buffalo, NY 14203, phone (716) 845-2300 in Buffalo, New York. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Breast Cancer and Coronary Artery Disease. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
Newly added in Buffalo
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
44 clinical trials at Roswell Park Comprehensive Cancer Center
·Clear filters·A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Intratumoral N17350 in Advanced Solid Tumors
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Brief Title Mechanisms of Cancer-Related Pain and Opioid Use Among Adolescents and Young Adult Sarcoma Survivors: Pilot Feasibility Study
Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes
Carcinogen and Toxicant Exposure Among Young Adults Who Co-Use Cigarettes, E-cigarettes and Cannabis (Co-Tox Study)
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Vitamin A Supplementation in Allogeneic Stem Cell Transplantation.
Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients
SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
AI Derived Biomarker to Select Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma
Pilot Study of Line-Field Confocal Optical Coherence Tomography for Detection of Mohs Micrographic Surgery Margins of Basal Cell Carcinomas
Effects of Tax Proposals and Cigarette Availability on Tobacco Purchasing
CapTemY90 for Grade 2/3 NET Liver Metastases
A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue
A Patient Navigation Program for Addressing Disparities in Breast Cancer Care
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
Common conditions studied in Buffalo
- Acute Myeloid Leukemia (12 active studies)
- Breast Cancer (7 active studies)
- Coronary Artery Disease (6 active studies)
- Endometrial Cancer (6 active studies)
- Malignant Solid Neoplasm (6 active studies)
- Stage II Lung Cancer AJCC v8 (6 active studies)
Leading research sponsors in Buffalo
- Roswell Park Cancer Institute
- State University of New York at Buffalo
- National Cancer Institute (NCI)
- Children's Oncology Group
- AstraZeneca
Frequently asked questions
How many paid clinical trials are currently recruiting in Buffalo?
There are approximately 415 recruiting clinical trials in Buffalo, New York listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Buffalo pay participants?
Most recruiting trials in Buffalo compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Buffalo?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Buffalo?
The most common conditions under active study in Buffalo include Acute Myeloid Leukemia (12), Breast Cancer (7), Coronary Artery Disease (6), Endometrial Cancer (6), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Buffalo?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Buffalo on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Buffalo?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Buffalo?
Recruiting research sites in Buffalo include Roswell Park Cancer Institute, Roswell Park Comprehensive Cancer Center, University at Buffalo, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Buffalo right now?
The largest active categories in Buffalo are Cancer & tumors (188), Neurology & pain (26), Cardiovascular (23). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Roswell Park Comprehensive Cancer Center?
Roswell Park Comprehensive Cancer Center is located at Roswell Pk Comprehensive Cancer Ctr, 665 Elm St, Buffalo, NY 14203. Use the Google Maps link in the intro above to get directions.
How do I contact Roswell Park Comprehensive Cancer Center?
You can reach Roswell Park Comprehensive Cancer Center by phone at (716) 845-2300. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.